The use of antihypertensive agents has increased in recent years and has been more marked among individuals in older age groups (65-74 years) than in middle-aged groups (45-54 years). Because hypertension is a strong risk factor for the development of congestive heart failure, more common use of antihypertensive agents would be expected to reduce the incidence of congestive heart failure. Examination of the national death statistics reveals decreases in congestive heart failure mortality at younger ages with mortality increases at older ages. The reasons for these divergent trends in congestive heart failure mortality in different ages and the apparent inconsistency with respect to the changes in the use of antihypertensive drugs are explored. We speculate that antihypertensive treatment does not completely prevent congestive heart failure but merely postpones its development by several decades. (Hypertension 1989;13(suppl I):I-74-I-79) P ersistently elevated blood pressure (BP) is associated with an increased risk of developing congestive heart failure (CHF). 1 Further, treatment for hypertension has been shown to be associated with a marked reduction in the incidence of CHF in several randomized controlled trials.
The use of antihypertensive agents has increased in recent years and has been more marked among individuals in older age groups (65-74 years) than in middle-aged groups (45-54 years). Because hypertension is a strong risk factor for the development of congestive heart failure, more common use of antihypertensive agents would be expected to reduce the incidence of congestive heart failure. Examination of the national death statistics reveals decreases in congestive heart failure mortality at younger ages with mortality increases at older ages. The reasons for these divergent trends in congestive heart failure mortality in different ages and the apparent inconsistency with respect to the changes in the use of antihypertensive drugs are explored. We speculate that antihypertensive treatment does not completely prevent congestive heart failure but merely postpones its development by several decades. (Hypertension 1989;13(suppl I):I-74-I-79) P ersistently elevated blood pressure (BP) is associated with an increased risk of developing congestive heart failure (CHF). 1 Further, treatment for hypertension has been shown to be associated with a marked reduction in the incidence of CHF in several randomized controlled trials. 2 Recent data from the National Health and Nutrition Examination Surveys (NHANES) indicate that the use of antihypertensive drugs has increased and that the average blood pressure level of the US population may be declining. 3 Therefore, it would be reasonable to expect that the increasing use of antihypertensive drugs with the concomitant lowering of BP may lead to a reduction in mortality due to CHF. In this article, we analyze and relate the changes in treatment for hypertension and the changes in CHF mortality. Therefore, we systematically consider the following points: 1) the national trends in CHF mortality in the population as a whole and in population subgroups based on age, sex, and race; 2) the relation between BP and CHF and whether this relation varies among different age groups; 3) the proportion of CHF that is "attributable" to hypertension; 4) the effect of treatment of hypertension on CHF in controlled trials and whether the effect is similar in patients with different severities of hypertension; and 5) the changes in treatment of hypertension during the last few decades.
Initially, we assess whether the changes in CHF mortality and the changes in treatment for hypertension show similar trends. We then attempt to explain the differences in these patterns.
Subjects and Methods

Sources of Data
Data for this article have been obtained from the following sources: 1) data on CHF (International Classification of Diseases [ICD] Codes 427.0 and 427.1 in the 8th revision and code 428 in the 9th revision) mortality from the National Center for Health Statistics.
3 CHF mortality data are based on age, sex, and race during the decade 1968-1978, during which period there were no revisions to the ICD codes; 2) data on treatment of hypertension for the periods 1960-1962 and 1976-1980 because there are no precise or easily agreed-on definitions for CHF, the national statistics on CHF mortality may not be entirely accurate. We have also examined data from the hospital discharge survey 13 (and R. Pokras, unpublished observations) and have observed trends in the hospital diagnosis for CHF that parallel the national statistics on CHF mortality. Although general changes in the diagnostic criteria for CHF could explain an overall increase in the incidence of CHF, decreases in the incidence of CHF in younger age groups, increases in older age groups, and differences in trends between blacks and whites during the same period argue against this possibility. Moreover, the overall increase in CHF deaths has been observed for 30 years and has paralleled the trend in mortality where CHF was considered to be the "underlying" or the "contributing" cause of death, thereby excluding the possibility of artifacts caused by shifts in categorization from contributing cause to underlying cause or viceversa. Although the absolute numbers of deaths attributed to CHF during any particular period may be questioned, we believe that the trends observed, especially those between different groups of individuals, are more likely to be real. Unpublished data from a British study on CHF morbidity also confirm this trend toward increased CHF mortality (C. Davidson, personal communication).
Second, data on CHF mortality based on age and data based on changes in treatment of hypertension are not available during identical periods. For example, age-specific CHF mortality data are available only from 1968 onward, whereas the NHANES and NHES were conducted during different periods that only partially overlap (NHES during 1960 -1962 , NHANES I during 1971 -1974 , and NHANES II during 1976 -1980 . 3 However, the trends in CHF mortality and in the treatment of hypertension appear linear. Therefore, the two trends can at least be used to compare whether they show similar trends. Third, CHF deaths by specific cause are not yet available. Therefore, even if treatment of hypertension truly led to a reduction in mortality due to CHF, this effect may be "diluted" or even apparently masked or reversed by changes in CHF death rates due to other causes. Fourth, data from epidemiological studies and clinical trials chiefly relate the levels of BP or the impact of antihypertensive treatment to CHF morbidity and not to CHF mortality. Instead, if we were to use CHF morbidity data from the national statistics, these data may be even less reliable compared with national mortality data. However, since the overall trends in CHF morbidity (obtained from the hospital discharge survey 13 ) and CHF mortality parallel each other, predicting the effect of BP changes on CHF mortality instead of on CHF morbidity may not matter as long as we restrict our comparisons to patterns of change. Fifth, the relation between BP and CHF may vary in different age, sex, and race groups. Data by age and sex are available from the Framing- ham Heart Study. 1 However, there are no epidemiological data relating BP with CHF in nonwhites. Therefore, in this analysis, we either had to assume that the relation between changes in BP and CHF were the same in blacks and whites or to limit interpretations of the national statistics on CHF mortality to whites only.
Results
National Trends in Congestive Heart Failure Mortality and Morbidity
Data obtained from the National Center for Health Statistics 3 indicate that the number of deaths due to CHF has increased more than fourfold during the period 1955-1983. For example, the number of deaths in which CHF was considered to be the underlying cause increased from about 6,000 in 1955 to more than 33,000 by 1983 (Table 1) . A parallel increase occurred in the number of deaths in which CHF was considered to have been a contributing cause, from 51,000 in 1955 to about 255,000 in 1983. Although a substantial part of this increase can be explained by the aging of the population, the ageadjusted death rates also show a twofold increase. For example, the age-adjusted death rates where CHF was the underlying cause increased from 3.8/ 100,000 in 1968 to about 7.1/100,000 by 1984. The incidence of deaths due to CHF increased exponentially with age in both sexes and in all races. CHF mortality is about 1 Vi times commoner in blacks and other racial groups than in whites. Differentials are greater at younger than older ages (Table 2) .
For the US population as a whole, the ageadjusted death rates for CHF have increased; however, this pattern is not shared by all age and race groups. For example, during the period 1968-1978, overall age-adjusted death rates increased by 21%. During this period, however, blacks experienced a 17% decline in CHF mortality and whites, a 32% increase (Table 3) . These changes were similar in men and women. In both racial groups, CHF mortality declined in younger age groups, whereas in older age groups, there were increases. In whites, the decline in CHF mortality was observed only up to the age group 45-54 years, whereas in blacks, the decline was observed even among the 65-74-year age group. Paralleling the increase in deaths from CHF, the rate of hospitalization for CHF has shown a marked increase. For example, the number of hospital discharges where CHF was the first listed diagnosis increased from about 155,000 in 1970 to 585,000 by 1985.' 3 It is difficult to assess whether this increase involves any specific etiologies, but available data from national hospital discharge statistics indicate a substantial increase in hospitalizations for cardiomyopathy (e.g., the first listed diagnosis of cardiomyopathy increased from about 8,000 in 1970 to 49,000 by 1985). However, these data should be cautiously interpreted because classification into various subcategories based on hospital discharge data may not be entirely reliable. Moreover, the hospital discharge data, subdivided according to whether CHF was associated with a history of hypertension or by age, race, and sex, are not available.
Etiologic Factors for Congestive Heart Failure
The Framingham Heart Study 1 is the only community study in which detailed analyses of the etiologic factors for CHF are available. In this study, 55% of patients who developed CHF had a history of hypertension, with as much as one third of CHF being attributed to hypertension (R.D. Abbott, personal communication). By contrast, the available data from the hospital-based studies (which are more recent but may also have marked selection biases) suggest that the percent of CHF attributable to underlying hypertension appears to be somewhat lower 1516 than that suggested by the Framingham Study (Table 4) . Based on the available data, it is not clear what proportion of CHF in the community can be attributed to hypertension.
Interaction Between Blood Pressure Levels, Age, and Development of Congestive Heart Failure
We examined the relation between BP levels recorded in [1969] [1970] [1971] [1972] Values are expressed as percent. The percentages of the different categories do not add to exactly 100% because data from other etiologies are not tabulated here and some patients may have more than one etiology.
*Based on an analysis of 2,486 subjects free of congestive heart failure at examinations conducted in 1969-1972 and then followed up for 10 years (R.D. Abbott, personal communication, 1987).
during the subsequent 10 years in 1,089 men and 1,397 women who had not yet developed CHF at entry into the Framingham Heart Study ( Figure 1 ). It appears that, in younger individuals (45-64 years old), the slope relating systolic BP to the subsequent development of CHF was steeper (a fivefold increase in CHF when systolic BP increased from 120 mm Hg to 160 mm Hg). The slopes relating systolic BP to subsequent CHF varied significantly by age (p<0.05 for interaction). This would suggest that treatment of hypertension in elderly individuals is likely to provide less proportionate and absolute reductions in CHF compared with similar BP reductions in younger individuals. However, because the prevalence of hypertension is substantially higher in older compared with younger individuals, 3 the total number of CHF deaths that could be prevented by antihypertensive treatment may be similar. Table 5 tabulates the results of treatment of hypertension on CHF in the randomized trials. 4 -12 It appears that, in patients with severe hypertension or in those with moderate hypertension and endorgan damage, treatment substantially decreased the incidence of CHF (one in 564 in treated patients compared with 33 in 559 in control patients; odds ratio of 0.13). By comparison, the benefit was smaller in patients with moderate hypertension who had no end-organ damage (45 in 2,962 in treated patients compared with 63 in 2,974 in control patients; odds ratio of 0.73). Note that most of these events are based on data from two trials in the elderly, and this finding could also account for the lesser relative benefit. Similar data are not yet available from the trials of mild hypertension. However, one may conjecture (by extrapolating from the available data) that the reduction in CHF might be smaller than that seen in patients with moderate hypertension. If this is true, then the overall impact of treatment of hypertension in preventing CHF in an unselected population (which consists mostly of individuals with mild hypertension) is likely to be even more modest. Most trials of hypertension used diuretic agents to reduce BP. It is also theoretically possible that diuretic drugs may delay or mask the diagnosis of CHF if such use prevented the development of signs of congestion without actually affecting cardiac dysfunction. If this were the case, the results of the randomized trials suggesting a large benefit of treatment in patients with severe hypertension during the few years of the trial may be unduly optimistic. Consequently, one may expect that changes in antihypertensive treatments will influence secular trends in CHF mortality only to a moderate degree. Table 6A outlines the changes in treatment for hypertension in the age groups 45-74 years, subdivided on the basis of race and sex from 1960-1962 and from 1976-1980. Table 6B outlines the average reduction in systolic BP in whites and blacks. It is evident that, between these intervals, use of antihypertensive drugs increased with age and has been more marked in black than in white women. Concomitantly, the average systolic BP had the greatest decline in older individuals with a more striking decrease in blacks compared with whites.
Effect of Treatment of Hypertension on Congestive Heart Failure
Secular Trends in Antihypertensive Treatment
Comparison of Secular Trends in Congestive Heart Failure With Trends in Coronary Heart
Disease and Strokes Table 7 provides data on changes in mortality due to CHF, coronary heart disease, and strokes in various age groups from 1968 to 1978.
While CHD and stroke mortality show about a 28% and a 39% decrease, respectively, that is of similar magnitude in all age groups, there is a trend toward less reduction or even an increase in CHF deaths with increasing age. These anomalous changes in CHF mortality are difficult to explain, as there does not seem to be any obvious etiology that shows a similar trend.
Discussion
It is evident from the preceding sections that the changes in CHF mortality have not paralleled changes in BP treatment or in secular trends for strokes or coronary heart disease. These disparities cannot be easily explained. We speculate that the relation between BP reduction and the change in CHF mortality is complex and is influenced by the individual's age, BP level, and the presence or absence of other cardiac diseases. The effect on CHF of treating hypertension in elderly individuals or in those with mild hypertension may be somewhat smaller than that predicted from the clinical trials, many of which enrolled younger patients with severe hypertension or with moderate hypertension and end-organ damage. It is also possible that the benefits that may accrue by the national increase in the treatment of hypertension on CHF might be obscured by changes in other categories of CHF death and the problems associated with the uncertain categorization of deaths due to CHF in national statistics. It is possible that the treatment of hypertension leads to postponement rather than actual prevention of CHF. This would be consistent with the observed decrease in CHF mortality in younger individuals and an increase in older individuals. The increase in CHF mortality, especially in the elderly, may also be due to better initial survival after myocardial infarction but later development of CHF.
The validity of the diagnosis of CHF based on death certificates, which forms the basis for the data on national trends, should be explored in future studies. Changes in criteria for the diagnosis of CHF and a lower threshold for labeling elderly patients as having CHF may have also contributed to the apparent increase. Results of a~ community study in Rochdale, England, where all diagnoses of CHF were verified by a cardiologist, also show an increase in CHF incidence (C. Davidson, personal communication).
Although the exact reasons for the differing trends in CHF mortality in middle-aged and older age groups are not readily apparent, the data are consistent with a model in which antihypertensive treatment or better management of myocardial infarction patients initially slows but does not arrest the development of CHF. Once CHF develops, treatment with diuretic drugs (for hypertension and CHF) may delay deterioration of ventricular function and ultimate death. This could lead to a reduction in CHF-related deaths in middle age and an apparent increase in similar deaths in old age.
